Lawmakers on a major GOP-led House health panel are set to question top drug supply-chain industry group leaders Wednesday, as economic anxieties are already shaping up to be a major theme in the 2026 midterms.
This isn’t the first time in recent years that Congress has hauled in leading players in the pharmaceutical industry. But it comes as health care costs are of particular concern for voters. The enhanced Affordable Care Act tax credits expired at the end of 2025 and Congress hasn’t been able to come to an agreement on extending them, which means that marketplace insurance is more ...